20/20 Biolabs, Inc. (AIDX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on April 1, 2026, by 20/20 Biolabs, Inc., a Delaware corporation trading on The Nasdaq Stock Market under the symbol AIDX. The report serves to disclose the issuance of a press release on March 31, 2026, detailing the Company's financial results for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K document.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed within the text of this filing. The document solely acts as a notification of the release of the annual results.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in the accompanying press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for the year ended December 31, 2025.
- Verify the Company's status as an Emerging Growth Company, as indicated by the checkmark in the filing.
- Confirm the trading symbol AIDX on The Nasdaq Stock Market LLC.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per this 8-K's disclaimer.